S1PR1 and myeloid sarcoma: Fingolimod modulates the activity of sphingosine-1-phosphate receptors (S1PR1), thereby inhibiting T lymphocyte migration from the central nervous system [42] lymph nodes, and thus acts on the first step of MS—neuroinflammatory.